Ranger Biotechnologies A/S: Financial statements 2012
CVR: 32280404
Source: annual report 2012, Danish Business Authority
01/01/2012 – 31/12/2012
Ranger Biotechnologies A/S (CVR 32280404) has filed annual accounts for 2012. In 2012, the company reported a gross profit of DKK -755,567 and a net result of DKK -1,246,409. Equity in the 2012 report amounted to DKK 5,644,798. The solvency ratio was 90.9%.
- Gross Profit
- DKK -755,567
- Profit/Loss
- DKK -1,246,409
- Equity
- DKK 5,644,798
- Total Assets
- DKK 6,206,716
Official annual report
Keep an eye on Ranger Biotechnologies A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringAbout Ranger Biotechnologies A/S
Ranger Biotechnologies A/S is a Danish company of the type Aktieselskab based in Odense SØ, founded in 2009. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named MIRRX THERAPEUTICS A/S and MIRX THERAPEUTICS A/S. The management consists of Hans Thorleif Møller. The board consists of Christina Møller Udesen (chair), Hans Thorleif Møller, Kasper Tvede Larsen and Søren Tvede Larsen. The company is owned by QUERDENKER ApS and Outlate Holding ApS. The company has 1 employee (2025). In 2025, the company reported a gross profit of DKK -409,444 and a net result of DKK -843,419 compared with DKK -1,138,092 the year before. Equity in the 2025 report amounted to DKK 711,273.